Dr. Saad Z. Usmani on Carfilzomib and Filanesib in Multiple Myeloma
Saad Z. Usmani, MD, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma.
Saad Z. Usmani, MD, director, Plasma Cells Disorder Program, Levine Cancer Institute/Carolinas Healthcare System, discusses the combination of carfilzomib and filanesib as a treatment for multiple myeloma. Usmani said a recent phase II study showcased a response rate of 14% in the carfilzomib-only arm, while a response rate of 35% was seen in the arm with patients receiving a combination of carfilzomib and filanesib.
Usmani said the regimen was efficacious, though the main question still persisting post study is how much dosing of carfilzomib should be included in an upcoming phase III study.
Lisaftoclax Plus Pd Demonstrates Strong Response and Safety in RRMM
December 10th 2024Lisaftoclax, a BCL-2 inhibitor, demonstrated efficacy and tolerability in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma as well as amyloidosis.
Read More
